白细胞介素11和结缔组织生长因子的表达与乳腺癌发生骨转移的关系

The relationship of IL-11 and CTGF expression with the bone metastasis of breast cancer

目的探讨白细胞介素11（IL-11）和结缔组织生长因子（CTGF）在乳腺癌骨转移中的作用。方法本研究为病例对照研究。收集天津医科大学附属肿瘤医院2007年5月至2009年1月收治的180例乳腺癌患者，均经组织学病理证实；按是否发生骨转移分为乳腺癌骨转移组90例、乳腺癌无骨转移组90例。健康对照组为同期本院20名健康体检者，均排除内分泌代谢性疾病和其他慢性疾病史。抽取外周血标本，应用酶联免疫法定量检测IL-11与CTGF的表达情况。同时收集乳腺病理科有完整存档资料的40例有骨转移和40例无骨转移的乳腺癌患者相应的肿瘤组织，采用组织芯片技术，应用免疫组化方法，检测肿瘤组织中二者的表达情况。统计学分析采用，检验、t检验及方差分析。结果IL-11和CTGF的血清浓度在骨转移组和无骨转移组分别为（242．9±56．3）、（85．9±35．7）μg／L及（15．6±7．4）、（15．0±7．0）μg／L，其中IL-11浓度在骨转移组明显高于无骨转移组，差异有统计学意义（F=43．532，P〈0．01），而CTGF浓度在两组间差异无统计学意义（F=3．007，P〉0．05）。IL-11和CTGF的高表达率在骨转移组和无骨转移组分别为57．5％、14．3％和17．5％、14．3％，其中IL-11的高表达率在骨转移组明显高于无骨转移组（X2=36．626，P〈0．01），而CTGF的高表达率在两组间差异无统计学意义（X2=0．370，P〉0．05）。结论IL-11的表达与乳腺癌骨转移的发生相关，高表达IL-11的乳腺癌可能更易发生骨转移。

Objective To investigate the role of IL-11 and CTGF in bone metastasis of breast cancer. Methods A total of 180 pathologically confirmed breast cancer patients in Tianjin Medical University Cancer Institute and Hospital were enrolled, 90 of which had bone metastasis. Twenty healthy people who took physical examination at the same period were adopted as controls, excluding those with endocrine or metabolic disease or other chronic diseases. Peripheral blood samples were collected and ELISA was employed to detect IL-11 and CTGF expression. Forty paraffin-embedded breast cancer tissue sections from those with bone metastasis and forty tissue sectioned from those without bone metastasis were detected for IL-11 and CTGF expression with immunohistochemisty. Results Serum IL-11 level was （242. 9 ± 56. 3 ） μg/L in the group with bone metastasis and （85.9 ±35.7） μg/L in the group without bone metastasis, with a significant difference （F = 43. 532,P 〈 0. 01 ）. Serum level of CTGF was （ 15.6 ± 7.4） μg/L in the group with bone metastasis and （ 15.0 ±7.0 ） μg/L in the group without bone metastasis, with no significant difference （ F = 3. 007 ,P 〉 0. 05 ）. The rate of positive immunohistochemical staining for IL-11 in the group with bone metastasis （57.5%） was significantly higher than that in the group without bone metastasis （ 14.3% ） （X2 = 36. 626, P 〈 0. 01 ）. There was no significant difference in the positive rate of CTGF expression between the group with bone metastasis （ 17.5% ） and the group without metastasis （ 14. 3% ） （X2 = 0. 370, P 〉 0. 05 ） . Conclusions IL-11 expression is correlated with bone metastasis of breastcancer. Breast cancer patients with high IL-11 expression are more prone to develop bone metastasis. （ Chin J Lab Med,2013 ,36：68-71 ）